Mason Carrico
Stock Analyst at Stephens & Co.
(3.72)
# 768
Out of 5,124 analysts
77
Total ratings
48.53%
Success rate
9.57%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $237.42 | -1.02% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.98 | +1.01% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $74.75 | +1.67% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $12.08 | -8.94% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $37.08 | +80.69% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $141.33 | -25.71% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $18.32 | -23.58% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $19.81 | +101.92% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $112.51 | +2.21% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $43.63 | +3.14% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $101.87 | -46.01% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $5.21 | +15.16% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $23.94 | -28.99% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $66.43 | -21.72% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $6.13 | +226.26% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $39.00 | +5.13% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $237.42
Upside: -1.02%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.98
Upside: +1.01%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $74.75
Upside: +1.67%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $12.08
Upside: -8.94%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $37.08
Upside: +80.69%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $141.33
Upside: -25.71%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $18.32
Upside: -23.58%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $19.81
Upside: +101.92%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $112.51
Upside: +2.21%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $43.63
Upside: +3.14%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $101.87
Upside: -46.01%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.21
Upside: +15.16%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $23.94
Upside: -28.99%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $66.43
Upside: -21.72%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $6.13
Upside: +226.26%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $39.00
Upside: +5.13%